Account
Inquiry
Tirzepatide pens contain a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This pharmaceutical grade compound demonstrates superior efficacy for glucose control and weight management compared to single agonists.
Our tirzepatide pens formulation features a PEG-modified lysine side chain that enhances water solubility while maintaining biological activity. The compound has shown promising results in clinical trials, with average weight reduction reaching 20.9% at the 15mg dose level over 72 weeks.
The tirzepatide pens are supplied as lyophilized white powder in sterile vials. Each pen contains precisely measured doses of the active pharmaceutical ingredient with 99.9% purity. The molecular structure (C225H348N48O68) has been optimized for stability and bioavailability.
As a research chemical, tirzepatide pens offer scientists a powerful tool for studying metabolic disorders. The dual agonist mechanism provides unique opportunities to investigate GIP and GLP-1 receptor interactions and their effects on glucose metabolism and weight regulation.
Our manufacturing process ensures batch-to-batch consistency in all tirzepatide pens. Strict quality control measures are implemented at every production stage to guarantee pharmaceutical grade purity and potency. The product is supplied in temperature-controlled packaging to maintain stability during transit.
